The importance of oxidative stress in patients with chronic renal failure whose hypertension is treated with peritoneal dialysis

Cell Biochemistry and Function

Volumn 29, Issue 3, 2011, Pages 249-254

  Demirci, Şerafettin ^a   Şekeroǧlu, Mehmet Ramazan ^a   Noyan, Tevfik ^a   Köçeroǧlu, Ruşen ^a   Soyoral, Yasemin Usul ^a   Dülger, Haluk ^a   Erkoç, Reha ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Antioxidant defense; Chronic renal failure; Hypertension; Oxidative stress; Peritoneal dialysis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MYELOPEROXIDASE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; MALE; OXIDATION; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTIOXIDANTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; NEUTROPHIL ACTIVATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PEROXIDASE; SUPEROXIDE DISMUTASE;

EID: 79953717094     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1744     Document Type: Article

References (37)

1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
2. Gokal R, Mallick NP. Peritoneal dialysis. Lancet 1999; 353: 823-828.
3. Noyan T, Sahin I, Sekeroglu MR, Dulger H. The serum vitamin C levels in Behcet's disease. Yonsei Med J 2003; 5(44): 771-778.
4. Engin A, Bozkurt BS, Altan N, Memis L, Bukan N. Nitric oxide-mediated liver injury in presence of experimental bile duct obstruction. World J Surg 2003; 27(3): 253-255.
5. Öǧüş E, Yilmaz FM, Yilmaz H, Durunay M, Yücel D. Serum malondialdehyde levels and susceptibility to oxidation in patients undergoing hemodialysis and peritoneal dialysis. T Klin J Med Sci 2004; 24: 316-322.
6. Rosenmund A, Binswanger U, Straub PW. Oxidative injuiry to erythroctyes, cell rigidity, and splenic hemolysis in haemodialialyzed uremic patients. Ann Intern Med 1975; 82: 460-465.
7. Van Heyningen R, Harding JJ. Do aspirin-like analgesics protect againts cataract? A case-control study. Lancet 1986; 1: 1111-1113.
8. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem 1993; 39: 2522-2526.
9. Witko-Sarsat V, Friedlander M, Capeiller-Blandin C, et al. Advanced oxidized protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
10. Goth L. A simple method for determination of serum catalase activity, and revision of reference range. Clin Chim Acta 1991; 196: 143-151.
11. Teixeria A, Morfim MP, de Cordova CA, Charao CC, de Lima VR, Creczynski-Pasa TB. Melatonin protects against pro-oxidant enzymes and reduces lipid peroxidation in distinct membranes induced by the hydroxyl and ascorbyl radicals and by peroxynitrite. J Pineal Res 2003; 35: 262-268.
12. Pleban PA, Munyani A, Beachum J. Determination of selenium concentration and glutathione peroxidase activity in plasma and erytrocytes. Clin Chem 1982; 28: 311-316.
13. Kocak H, Gumuslu S, Sahin E, et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009; 14(3): 273-280.
14. Fassett RG, Driver R, Healy H, et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients an observational study. BMC Nephrol 2009; 12; 10-18.
15. Ozden M, Maral H, Akaydin D, Cetinalp P, Kalender B. Erytrocyte glutathione peroxidase activity plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002; 35: 269-273.
16. Samouilidou E, Grapsa E. Effect of dialysis on plazma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure. Blood Purif 2003; 21: 209-212.
17. Celiker H, Elkiran B, Ilhan N, Gunal AI, Dogukan A. The effects of hemodialysis and peritoneal dialysisi on oxidative stress parameters. Turk Nephrol Dial Transplant 2001; 10(2): 88-92.
18. Sanaka T, Higuci C, Shinobe T. Lipid peroxidation as an indicator of biocompatibility inhaemodialysis. Nephrol Dial Transplant 1995; 10: 34-38.
19. Maher ER, Wickens DG, Griffin JF, Kyle P, Curtis JR, Dormandy TL. Increased free radical activity during haemodialysis? Nephrol Dial Transplant 1987; 2: 169-171.
20. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Advanced oxidation protein products as a novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-2532.
21. Furuya R, Hiromichi K, Mari O, Takahashi M, Miyaki A, Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009; 112: 255-261.
22. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-1169.
23. Hörl WH, Feinstein EL, Wanner C, Frischmuth N, Gösele A, Massry SG. Plasma levels of main glanulocyte components during hemodialysis. Comparison of new and reused dialyzers. Am J Nephrol 1990; 10: 53-57.
24. Noyan T, Avci G, Sekeroglu MR, Erkoc R. The investigation of relationship between secondary hyperparathyroidism and oxidative stress in patients with chronic kidney disease. Turk Nephrol Dial Transplant 2009; 18(2): 69-75.
25. Maile E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int 2003; 64: 1956-1967
26. Mimic-Oka J, Simic T, Pljesa M, Stupar N, Turković S. Oxidative modifications of plasma proteins in different stages of chronic renal failure. Med Biol 2001; 8: 1-5.
27. Yazici C, Kose K. Oxidative stress and "biomarker"s in chronic renal failure. Turk Soc Nephrol 2004; 13(3): 117-124.
28. Zwolińska D, Grzeszczak W, Kiliś-Pstrusińska K, Szprynger K, Szczepańska M. Lipid peroxidation and antioxidant enzymes in children with chronic renal failure. Pediatr Nephrol 2004; 19: 888-892.
29. Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57: 10-15.
30. Van Den Branden C, Ceyssens B, De Craemer D, et al. Antioxidant enzyme gene expression in rats with remnant kidney induced chronic renal failure. Exp Nephrol 2000; 8: 91-96.
31. Avissar N, Ornt DB, Yagil Y, et al. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 1994; 266: C367-C375.
32. Yawata Y, Jacob HS. Abnormal red cell metabilismin patients with chronic uremia: nature of the defect and its persistence despite adequate hemodialysis. Blood 1975; 45: 231-239.
33. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 2004; 14: 64-71.
34. Hamilton CA, Miller WH, Al-Benna S, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004; 106: 219-234.
35. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxidative stress. Curr Opin Cardiol 2007; 22(4): 311-315.
36. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-638.
37. Nishiyama A, Yoshizumi M, Rahman M, et al. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int 2004; 65: 972-981.